...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM - High Level Summary
Hi KBC, Don said at the meeting that the 34 million shares (roughly) was basically some sort of accounting number and in the final version that will become 99 million (same as Zenith currently) in the final iteration, before any further investment in the newco. He said that it is being done in such away as to avoid a tax bill for shareholders and that if anyone wants a detailed explanation of the process they should call Brad Cann because Don said he can't explain it.
Share
New Message
Please login to post a reply